Gradalis Competitors, Revenue and Alternatives
Estimated Revenue & Financials
- Gradalis's estimated annual revenue is currently $6.7M per year.
- Gradalis's estimated revenue per employee is $155,000
- Gradalis's total funding is $40M.
- Gradalis has 43 Employees.
- Gradalis grew their employee count by 43% last year.
- Gradalis currently has 1 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|Food Safety Net...||$49.8M||321||5%||N/A|
|Santa Cruz Biot...||$27M||174||N/A||N/A|
|Family Tree DNA||$6.2M||40||18%||N/A|
|VGXI, Inc. - cG...||N/A||49||N/A||N/A|
What Is Gradalis?
We are a late-stage biopharmaceutical company focused on the development and commercialization of novel personalized therapeutics to treat cancer. We are developing Vigil®, our proprietary immunotherapy platform in multiple advanced cancer indications.keywords:N/A
Number of Employees
Employee Growth %
|Meghan Manley||Senior Project Manager||Email Available|
|David Shanahan||Chief Executive Officer & Chairman of the Board||Email Available|
|Luisa Manning||VP of Medical & Scientific Affairs||Email Available|
|Ruth Chavez||Executive Assistant to President|
|John Nemunaitis||Chief Medical Officer||Email Available|
|Gladice Wallraven||Vice President, Clinical and Regulatory Operations||Email Available|
|David Shanahan||Chairman & CEO||Email Available|
|Walter Chen||Vice President - Finance & Corporate Development (and Board Secretary)||Email Available|
|Kay Easterwood-Sanchez||Data Manager|
Global RNA Drugs Market 2019-2025 is a comprehensive report which provides a detailed overview of the major driver, opportunities, ...
DALLAS, March 04, 2019 (GLOBE NEWSWIRE) -- Gradalis, Inc., a clinical-stage immunotherapy company developing investigational ...
Alnylam Pharmaceuticals, Arrowhead, Dicerna Pharmaceuticals, Gradalis, miRagen Therapeutics, among others, hold the substantial market ...